Literature DB >> 1533419

5-Hydroxytryptamine3 receptors sited on cholinergic axon terminals of human cerebral cortex mediate inhibition of acetylcholine release.

G Maura1, G C Andrioli, P Cavazzani, M Raiteri.   

Abstract

Synaptosomes prepared from freshly obtained human cerebral cortex and labeled with [3H]choline have been used to investigate the modulation of [3H]acetylcholine ([3H]ACh) release by 5-hydroxytryptamine (5-HT). The Ca(2+)-dependent release of [3H]-ACh occurring when synaptosomes were exposed in superfusion to 15 mM KCl was inhibited by 5-HT (0.01-1 microM) in a concentration-dependent manner. The effect of 5-HT was mimicked by 1-phenylbiguanide, a 5-HT3 receptor agonist, but not by 8-hydroxy-2-(di-n-propylamino)tetralin, a 5-HT1A receptor agonist. The 5-HT3 receptor antagonists tropisetron and ondansetron blocked the effect of 5-HT, whereas spiperone and ketanserin were ineffective. It is suggested that cholinergic axon terminals in the human cerebral cortex possess 5-HT receptors that mediate inhibition of ACh release and appear to belong to the 5-HT3 type.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1533419     DOI: 10.1111/j.1471-4159.1992.tb10983.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  17 in total

Review 1.  Multitude of ion channels in the regulation of transmitter release.

Authors:  R Rahamimoff; A Butkevich; D Duridanova; R Ahdut; E Harari; S G Kachalsky
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-02-28       Impact factor: 6.237

2.  Characterization of a human 5-hydroxytryptamine3 receptor type A (h5-HT3R-AS) subunit stably expressed in HEK 293 cells.

Authors:  A G Hope; J A Peters; A M Brown; J J Lambert; T P Blackburn
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

3.  Comparison of the effects of the 5-HT3 receptor antagonists WAY-100579 and ondansetron on spatial learning in the water maze in rats with excitotoxic lesions of the forebrain cholinergic projection system.

Authors:  H Hodges; P Sowinski; J J Turner; A Fletcher
Journal:  Psychopharmacology (Berl)       Date:  1996-05       Impact factor: 4.530

Review 4.  The non-antiemetic uses of serotonin 5-HT3 receptor antagonists. Clinical pharmacology and therapeutic applications.

Authors:  A J Greenshaw; P H Silverstone
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

5.  Regulation of the septal pacemaker theta rhythm by the cervical nuclei of the midbrain.

Authors:  V F Kichigina; T A Gordeeva
Journal:  Neurosci Behav Physiol       Date:  1996 Nov-Dec

6.  Background activity of rabbit hippocampal neurons in conditions of functional exclusion of structures which regulate the theta rhythm.

Authors:  V F Kichigina; T A Kudina; K I Zenchenko; O S Vinogradova
Journal:  Neurosci Behav Physiol       Date:  1999 Jul-Aug

7.  The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens.

Authors:  Mei Huang; Anna R Felix; Dorothy G Flood; Chaya Bhuvaneswaran; Dana Hilt; Gerhard Koenig; Herbert Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2014-05-09       Impact factor: 4.530

8.  Modulation of cortical acetylcholine release by serotonin: the role of substance P interneurons.

Authors:  T J Feuerstein; O Gleichauf; G B Landwehrmeyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-11       Impact factor: 3.000

9.  Serotonergic modulation of anticholinergic effects on cognition and behavior in elderly humans.

Authors:  J T Little; A Broocks; A Martin; J L Hill; L E Tune; C Mack; M Cantillon; S Molchan; D L Murphy; T Sunderland
Journal:  Psychopharmacology (Berl)       Date:  1995-08       Impact factor: 4.530

10.  5-HT3 receptor ligands lack modulatory influence on acetylcholine release in rat entorhinal cortex.

Authors:  R M Johnson; G T Inouye; R M Eglen; E H Wong
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-03       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.